When molecular biology transforms clinical oncology: the EGFR journey in colorectal cancer

When molecular biology transforms clinical oncology: the EGFR journey in colorectal cancer

The discovery of growth factors and their involvement in cancer represents the foundation of precision oncology. The preclinical and clinical development of agents targeting epidermal growth factor receptor (EGFR) in colorectal cancer (CRC) were accompanied by big hype and hopes, though the clinical...

Full description

Saved in:

Bibliographic Details
Main Authors:	Pietro Paolo Vitiello, Nadia Saoudi González, Alberto Bardelli
Format:	Article
Language:	English
Published:	Wiley 2025-02-01
Series:	Molecular Oncology
Subjects:	precision medicine colorectal cancer EGFR drug resistance translational research
Online Access:	https://doi.org/10.1002/1878-0261.13754
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

EGFR inhibitors in the treatment of colorectal cancer
by: M. В. Zabelin, et al.
Published: (2018-09-01)

Hyodeoxycholic acid inhibits colorectal cancer proliferation through the FXR/EREG/EGFR axis
by: Qiang Pang, et al.
Published: (2025-01-01)

Study of the expression of oncoprotein p53, EGFR in colorectal carcinomas with different proliferative activity
by: I.S. Shponka, et al.
Published: (2023-04-01)

Gasdermin D regulates the activation of EGFR in colorectal cancer
by: Ying Li, et al.
Published: (2024-12-01)

Efficacy and Safety of Chemotherapy or EGFR‐TKIs as First‐Line Therapy in NSCLC Patients Harboring Non‐Ex 20 Ins Uncommon EGFR Mutations: A Retrospective Study in China
by: Chen Liao, et al.
Published: (2025-01-01)

Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors
by: Nathaniel J. Myall, MD, et al.
Published: (2025-02-01)

Emerging targeted therapies in oral oncology: Focus on EGFR inhibition
by: Vishnu Priya Veeraraghavan, et al.
Published: (2024-09-01)

CircUCK2(2,3) promotes cancer progression and enhances synergistic cytotoxicity of lenvatinib with EGFR inhibitors via activating CNIH4–TGFα–EGFR signaling
by: Xindong Wei, et al.
Published: (2025-01-01)

Study Protocol of the Korean EGFR Registry: A Multicenter Prospective and Retrospective Cohort Study in Nonsmall Cell Lung Cancer Patients With EGFR Mutation
by: Chang Dong Yeo, et al.
Published: (2025-01-01)

EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis
by: Ao Liu, et al.
Published: (2024-11-01)

Clinical characteristics of EGFR-ctDNA shedders in EGFR-mutant NSCLC patients
by: Martina Ruglioni, et al.
Published: (2025-02-01)

Non-small Cell Lung Cancer Cell Line PC-9 Drug-resistant Mutant Cell Line  Establishment and Validation of Their Sensitivity to EGFR Inhibitors
by: Tao HU, et al.
Published: (2024-11-01)

EGFR as a biomarker of smoking status and survival in oropharyngeal squamous cell carcinoma
by: Shanmugappiriya Sivarajah, et al.
Published: (2019-01-01)

Design, synthesis, and apoptotic antiproliferative action of new benzimidazole/1,2,3-triazole hybrids as EGFR inhibitors
by: Alshimaa A. Y. Ahmed, et al.
Published: (2025-01-01)

Baicalein inhibits PRRSV through direct binding, targeting EGFR, and enhancing immune response
by: Jing Wu, et al.
Published: (2025-01-01)

Responsive afatinib treatment in high-grade salivary gland ductal carcinoma and NSCLC with uncommon EGFR mutations: Treatment outcomes
by: Sivakamavalli Jeyachandran
Published: (2024-06-01)

EGFR inhibition augments the therapeutic efficacy of the NAT10 inhibitor Remodelin in Colorectal cancer
by: Yongbin Zheng, et al.
Published: (2025-02-01)

EGFR-targeting RNase A-cetuximab antibody-drug conjugate induces ROS-mediated apoptosis to overcome drug resistance in KRAS mutant cancer cells
by: Bita Jafary, et al.
Published: (2025-01-01)

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis
by: Shang‐Gin Wu, et al.
Published: (2025-01-01)

Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator’s Consortium Registry Analysis
by: Margaret Stalker, MD, et al.
Published: (2025-01-01)

Five-year follow-up study of stage I-IV rectal cancer including EGFR immunoexpression and p21 immunoactivity
by: Monika Kozłowska-Geller, et al.
Published: (2021-03-01)

Comparative analysis of EGFR mutations in circulating tumor DNA and primary tumor tissues from lung cancer patients using BEAMing PCR
by: Duhita Mirikar, et al.
Published: (2025-01-01)

Oncological aid for colorectal cancer patients in Tomsk area: ways of cancer prevention
by: L. D. Zhuykova, et al.
Published: (2014-12-01)

Discovery of potent allosteric antibodies inhibiting EGFR
by: Léxane Fournier, et al.
Published: (2024-12-01)

Study of the association of the known prognostic variables with EGFR expression in head and neck squamous cell carcinomas
by: Toyaja Jadhav, et al.
Published: (2023-07-01)

Vaccarin suppresses diabetic nephropathy through <?A3B2 pi6?>inhibiting the EGFR/ERK1/2 signaling pathway
by: Zhu Xuexue, et al.
Published: (2024-08-01)

Elucidating the potential of EGFR mutated NSCLC and identifying its multitargeted inhibitors
by: Anakha D. Rajeeve, et al.
Published: (2025-01-01)

Rebiopsy Enhances Survival with Afatinib vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan
by: Jerry Shu-Hung Kuo, et al.
Published: (2025-01-01)

Modulation of gut microbiota in targeted cancer therapy: insights on the EGFR/VEGF/KRAS pathways
by: Li Gong, et al.
Published: (2024-12-01)

Orthogonal validation of PROTAC mediated degradation of the integral membrane proteins EGFR and c-MET
by: Camilla Ruffilli, et al.
Published: (2025-01-01)

Machine learning-based identification of proteomic markers in colorectal cancer using UK Biobank data
by: Swarnima Kollampallath Radhakrishnan, et al.
Published: (2025-01-01)

The Electric Field Guided HaCaT Cell Migration Through the EGFR/p38 MAPK/Akt Pathway
by: Huajian Zhou, et al.
Published: (2024-12-01)

Patient Perspectives on Personalized Risk Communication Using Polygenic Risk Scores to Inform Colorectal Cancer Screening Decisions
by: Shauna R. Goldberg, MPH, et al.
Published: (2025-02-01)

Epsin3 promotes non-small cell lung cancer progression via modulating EGFR stability
by: Huiling Su, et al.
Published: (2025-02-01)

Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
by: Jing Zhang, et al.
Published: (2025-02-01)

A Case Report of EGFR-TKIs Resistant Secondary MET Gene Amplified  Lung Squamous Cell Carcinoma and Literature Review
by: Yalan LIU, et al.
Published: (2024-11-01)

Effects of EGFR-TKIs combined with intracranial radiotherapy in EGFR-mutant non-small cell lung cancer patients with brain metastases: a retrospective multi-institutional analysis
by: Mingfeng He, et al.
Published: (2025-01-01)

GRHL2-HER3 and E-cadherin mediate EGFR-bypass drug resistance in lung cancer cells
by: Fumiya Ito, et al.
Published: (2025-01-01)

Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation–Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)
by: Chee Khoon Lee, PhD, et al.
Published: (2025-02-01)

Impact of estimated glomerular filtration rate (eGFR) on in-hospital mortality: an age- and HIV status-specific retrospective cohort study in Uganda
by: Odong Christopher, et al.
Published: (2025-01-01)